迪索皮拉米德治疗对阻塞性缩性心肌病症患者功能能力改善的影响
Arda Güler1, Yunus Emre Erata1, Ayşe İrem Demirtola2
1University of Health Sciences, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, Department of Cardiology, Istanbul, Turkey.
International journal of cardiology
|December 20, 2024
概括
迪索皮拉米德显著改善了阻塞性多变性心肌病 (HCM) 患者的功能能力. 与对照组相比,使用迪索皮拉米德的患者的比例更高,实现了改善的NYHA类.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 增高性心肌病 (HCM) 是一种遗传性心脏病,其特征是左心室外流通道阻塞 (LVOTO).
- 阻塞性HCM (HOCM) 导致症状和不良后果,需要有效的治疗.
- 迪索皮拉米德 (disopyramide) 是一种负义无otropic 剂,用于缓解 HOCM 中的 LVOTO.
研究的目的:
- 评估迪索皮拉米德对HOCM患者功能能力的影响.
- 为了比较迪索皮拉米德和标准疗法 (β阻塞剂或通道阻塞剂) 之间的治疗反应率.
主要方法:
- 有症状的HOCM患者被分为迪索皮拉米德和对照组 (β-阻断剂/通道阻断剂).
- 治疗反应被定义为纽约心脏协会 (NYHA) 功能类中≥1阶段的改善.
- 分析了临床数据,NT-proBNP水平和LVOT梯度.
主要成果:
- 接受迪索皮拉米德治疗的62%的患者实现了≥1阶段的NYHA改善,而对照组的26%.
- 迪索皮拉米德的使用和左心室晚期加多增强 (LGE) 预测了功能改善.
- 没有观察到整体临床结果的显著差异,与disopyramide的副作用最小.
结论:
- 迪索皮拉米德显著提高HOCM患者的功能能力.
- 改善迪索皮拉米德的可用性至关重要,特别是在可用性有限的地区.
- 迪索皮拉米德为改善HOCM症状提供了一个可行的治疗选择.
更多相关视频
14:39Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
Published on: April 21, 2014
17.3K
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
1.7K
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
516
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
516
01:22Heart Failure Drugs: Diuretics
339
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
339
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
382
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
382
01:26Imbalances in Cardiac Output
1.3K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.3K
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:22Heart Failure Drugs: β-Blockers
315
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
315